Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Recipient : Tiumbio
Deal Size : Inapplicable
Deal Type : Inapplicable
TiumBio and Daewon Complete Phase 2 Merigolix Trial for Fibroids
Details : TU2670 (merigolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist, being investigated for uterine fibroids.
Product Name : TU2670
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2025
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Recipient : Tiumbio
Deal Size : Inapplicable
Deal Type : Inapplicable